Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2025)

Agios Pharmaceuticals' Other Non Operating Income history spans 5 years, with the latest figure at $113000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 93.04% year-over-year to $113000.0; the TTM value through Dec 2025 reached $2.0 million, down 69.85%, while the annual FY2025 figure was $2.0 million, 69.85% down from the prior year.
  • Other Non Operating Income reached $113000.0 in Q4 2025 per AGIO's latest filing, up from $67000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.5 million in Q2 2021 to a low of $67000.0 in Q3 2025.
  • Average Other Non Operating Income over 5 years is $1.9 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: soared 37.81% in 2024, then tumbled 95.94% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $3.3 million in 2021, then tumbled by 58.48% to $1.4 million in 2022, then grew by 26.23% to $1.7 million in 2023, then fell by 5.25% to $1.6 million in 2024, then crashed by 93.04% to $113000.0 in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Other Non Operating Income are $113000.0 (Q4 2025), $67000.0 (Q3 2025), and $523000.0 (Q2 2025).